TCTR20161117001尚未招募4 期
Bioequivalence study of pregabalin 25 mg capsule in Thai healthy volunteers
Ratchadapisek Sompoj Fund, Chulalongkorn University0 个研究点目标入组 24 人开始时间: 2016年11月17日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 50 Years（—）
- 性别
- All
入选标准
- •1. Subjects who are Thai male or female, aged 18 to 50 years.
- •2. Subjects whose BMI is 18-25 kg/m2.
- •3. Subjects who are healthy by medical history, physical examination and vital signs.
- •4. Subject whose screening visit laboratory values of blood tests including complete blood count, fasting blood sugar, blood urea nitrogen, serum creatinine, alkaline phosphatase, ALT, AST, total bilirubin, albumin, electrolytes are within the normal range or showing no clinically significant abnormalities as confirmed by the clinical investigator. Hepatitis Bs-antigen and anti-HIV are negative.
- •5. For female subjects:
- •Female subject who is in childbearing potential must have serum β-HCG negative and agrees to use an acceptable birth control method from visit 1 to the last visit. The acceptable birth control method is defined as a barrier method of contraception (including condoms, intrauterine device (IUD) and diaphragm with spermicial agent) or total abstinence from sexual intercourse from visit 1 to the last visit. Hormonal contraceptives are not acceptable.
- •Female subject who is in child bearing potential must agree not to become pregnant for the entire participation phase and must have a negative result for urine pregnancy test performing prior to dosing at phase I and II.
- •Female subjects can be those with non-childbearing potential which defined as female subjects with hysterectomy, both ovaries removed, surgically sterilized or postmenopausal (for at least 12 consecutive months of amenorrhea).
- •6. Subjects are able to understand the requirements of the study and voluntarily sign and date an informed consent, approved by the Independent Ethic Committee (IEC)/ Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.
排除标准
- •1. Subjects who are with a history/evidence of allergy or hypersensitivity to pregabalin or any related drug.
- •2. Subjects who have a history of any illness that, in the opinion of the clinical investigator, might confound the result of the study or pose an additional risk in administrating study drug to the subjects. This may include but not limited to: a history of relevant drug or food allergies; history or cardiovascular, gastrointestinal, central nervous system disease, renal and hepatic impairment; history or presence of clinically significant illness; or history of mental illness that may affect compliance with study requirements.
- •3. Subjects who are with a history of heavy smoking (more than 10 cigarettes per day) or moderate smoking (less than 10 cigarettes per day) and cannot omit smoking at least one day before the study and until the completion of the study phase.
- •4. Subjects who are with a history of alcoholic (more than 2 years) or moderate drinkers (more than 3 drinks per day †one is equal to one unit of alcohol: - one glass of wine, half pine of beer or one measure of spirit) or subjects who are with a history of any drug abuse.
- •5. Subjects who receive of any medical prescription within 14 days before the first administration of the study drug, especially drug related to the study drug metabolizing enzyme.
- •6. Female subjects who are pregnant or breast feeding.
- •7. Subjects who are participating in any investigational drug study or had been in any investigational drug study within 3 month prior to the screening visit.
研究者
相似试验
尚未招募
3 期
Bioequivalence study of pregabalin 75 mg capsule in Thai healthy volunteers-Thai healthy male and female subjects-Aged 18 †50 years -BMI were within 18ᆭ kg/m2-Good health confirming by physical and clinicalBioequivalencePharmacokineticPregabalinTCTR20170629003Faculty of Medicine, Chulalongkorn University24
已完成
4 期
Bioequivalence study of pregabalin 150 mg capsule in Thai healthy volunteersTCTR20161123001Ratchadapisek Sompoj Fund, Chulalongkorn University20
招募中
Unknown
Bioequivalence study of Empagliflozin 25 mg tabletIRCT20200105046010N83kharazmi company24
招募中
不适用
Bioequivalence of EmpaglifloziDetermination of plasma concentration of Empagliflozin 25 mg pharmaceutical product.IRCT20210201050197N5Shahid Beheshti University of Medical Sciences24
已完成
不适用
Bioequivalence Study of Two Formulations of Pregabalin Capsules 150 mgHealthyNCT02233777Dexa Medica Group20